BioVie updates investors on its Alzheimer’s and Parkinson’s clinical programs

BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients with Parkinson’s disease who were treated with the drug for 28 days.

https://www.proactiveinvestors.com/companies/news/...ams-1000514.html

 

Und es kommt noch mehr.

"The Company has determined to withdraw the Registration Statement and not pursue the public offering at this time."

https://quantisnow.com/insight/3792745  

Der Kurs ist fast festgenagelt um die 6 USD.